VYNE Therapeutics Inc.

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops distinct treatments for inflammatory and immune-mediated conditions where current therapies are insufficient. The company holds exclusive worldwide rights to research, develop, and commercialize products containing small molecule bromodomain and extra-terminal domain ("BET") inhibitors for treating human diseases. These rights were licensed from Tay Therapeutics Ltd., formerly In4Derm Ltd. ("Tay"). BET proteins are epigenetic enablers of transcription, regulating specific gene expression, and each BET protein has two bromodomains ("BD1" and "BD2") and one end terminal ("ET") domain. Through its agreement with Tay, VYNE gained access to a library of new small molecule BET inhibitor compounds, including those that inhibit both BD1 and BD2 ("pan-BD" BET inhibitor) and those that selectively inhibit BD2 ("BD2-selective" BET inhibitor). The company initially concentrated its development efforts on immune-mediated inflammatory diseases, which are not targets of other BET inhibitors currently in development. In August 2025, VYNE began a strategic review to explore options for maximizing stockholder value, including assessing its internal pipeline, financing, and strategic alternatives. This process involved evaluating opportunities for repibresib and VYN202. Concurrently, cost reductions were implemented to extend the company's cash runway. Following this review, VYNE entered into an Agreement and Plan of Merger and Reorganization, dated December 17, 2025, and amended on January 30, 2026, with Yarrow Biosciences, Inc. ("Yarrow"). Under this agreement, Yellow Merger Sub Corp., a direct, wholly owned subsidiary of VYNE, will merge with Yarrow, with Yarrow surviving as a wholly owned subsidiary of VYNE.